Page 55 - Medication Guide News Today

Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings Pfizer Inc. announced today that the U.S. Food and Drug Administration has notified the company that it will not meet the Prescription Drug User Fee Act goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for XELJANZXELJANZ XR for the treatment of adults with active ankylosing … Pfize...

Message : Required fields – Every year in the United States, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS), and there remains a high unmet need for new treatment options – – The designation is based on interim results from the Phase Ib M15-531 study investigating Venclexta plus azacitidine in people with previously untreated higher-risk MDS – – This is the 11th Breakthrough Therapy Designation for Genentech’s hematology medicines and the sixth for Ve...

Press release content from Business Wire. The AP news staff was not involved in its creation. New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A July 19, 2021 GMT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 19, 2021-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the final analysis of the Phase IIIb STASEY study, which confirm the favorable safety profile of Hemlibra ® (emicizumab-...

Merck known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for KEYTRUDA for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [combined positive score ] as determined by a U.S. Food and Drug Administration -approved … Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...

(BPT) - In 2021, it is estimated that more than 235,000 Americans may be diagnosed with lung cancer. The five-year survival for early forms of the disease is approximately 60

Press release content from Business Wire. The AP news staff was not involved in its creation.

ABBVie today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® plus VENCLEXTA ® VENCLYXTO ® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary … ABBVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study compar...

Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...

Jazz shares results from sleep medicine research and the development of novel therapeutic options for people living with sleep disorders DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals

DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be... | June 9, 2021